Rules & Guidelines for Abstract Submission

General Rules:

• Abstracts must be submitted in English.
• Abstract submission is via ISCO website only, it guarantees you free registration to ISCO 25 congress. Abstracts received after the deadline, will not be considered.
  • Please note: The email used for the person indicated as the presenting author during the submission process, must also be the same email used for the presenter during their registration process.
• The same person may serve as a presenting author on up to 2 abstracts.
• The Scientific Committee will determine whether the abstract will be accepted for a digital (e-Poster) display then a selected 3 highly scored posters will be considered for an oral presentation, with consideration given to the author’s preference
• The best (only one) of the 3 oral presentations will win the final ISCO GOT RESEARCHERS prize of 1000$
• Please contact us if you have not received confirmation that your abstract has been submitted.
• Emails regarding the acceptance/rejection will be sent to the corresponding author as soon as the decision is made.
• Being selected for E- Poster or oral presentation does not guarantee travel grant, airfare or accommodation
• Top selected 3 abstracts will be orally presented in the main hall of ISCO GOT RESEARCHERS’ scientific session in front of an international committee of expert researchers),
• Oral presentations are intended to be given in person, in Cairo Mariott Hotel, Ayda Ballroom, Zamalek, Cairo (specific presentation time and date will be disclosed later upon the notification of acceptance.)
• Oral Presentations are set to be physical, In case you are from a foreign country to Egypt and unable to come in person, the option is available to present virtually. Kindly indicate that in the form of submission (only for foreigners).

Oral Presentation & e- Poster formats and rules:

• E-Poster Display (to be displayed at e-Poster stations at the exhibition area of the congress), all wining abstracts will have the right to win an e-Poster display
• Top 3 abstracts will be invited for “ORAL PRESENTATION” in the main hall.

Guidelines for Submission:

• ​Presenting author’s contact details:
  • Full first and family name(s)
  • Email address
  • Affiliation details: department, institution / hospital, city state (if relevant), Country
  • Phone number
  • Author and co-authors’ details
• Abstract title– must be in UPPER CASE and limited to 25 words.
• Abstract text– limited to 300 words.
• Abstract topic– select the abstract topic per the list of topics.
  • List of Topics:
    • All Solid Tumors related research
    • Hematologic malignancies
    • Developmental Therapeutics—Immunotherapy, Targeted therapies and Tumor biology
    • Symptom Science and Palliative Care (related to oncology)
    • Quality Care/Health Services Research (related to oncology)
    • Prevention, Risk Reduction, and Genetics (related to oncology)
    • Care Delivery/Models of Care (related to oncology)
  • The abstract must be structured into the following sections as given in the template:
    • Introduction, Objectives.
    • Materials and Methods
    • Results
    • Conclusions
  • It is the responsibility of the authors to specify the name and designation of the presenting author (if not the principal author) and mention the full names of all co-authors with their affiliations.
  • It is the responsibility of the corresponding/principal authors to ensure that there is no conflict of interest, and all co-authors are in agreement with the submission of their study to the ISCO 2025 CONFERENCE
  • Statements like “results will be discussed” are not acceptable and may lead to a rejection of the abstract.
  • CASE REPORTS will not be entertained
  • Abstracts must contain data and meet international ethical standards.
  • Abbreviations should be defined.
  • Submissions may not contain patient names, hospital ID numbers or other identifying information.
  • The abstract text, as well as the abstract title and the list of authors will be reproduced exactly as submitted. No proof reading will be done.
  • Use generic names of drugs. The presentation must be balanced and contain no commercial or promotional content.
  • Please contact us if you have not received confirmation that your abstract has been submitted.
  • Please do not submit multiple copies of the same abstract.

 Cancellation:

 We require that all cancellations for abstracts submitted are made through email no later than March 30^th, 2025. Cancellations must be made by the principal author by his/her email only.

AUTHORS’ AGREEMENT:

• By submitting the abstract, the author/s confirms and agrees to the following:
  • All authors approve submitting this work for display during the conference days and/or presentation if selected.
  • The authors have done the work reported in the abstract and take full responsibility for the contents.
  • The authors agree to confine their presentation to information in the abstract.
  • The author will immediately notify the Scientific Committee if they are unable to make a presentation or if the presenting author is changed.
  • The authors guarantee that clinical studies have proceeded with official permission from the proper authorities.

• During abstract submission you will be asked to confirm that you agree to the following:
  • I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author may request to be copied on abstract correspondence.
  • I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission, and I am aware that it will be published as submitted.
  • The Abstract Submitter grants the Organizers a copyright license to reproduce, publish, translate, distribute, and display the text of the Content on a royalty-free, perpetual, irrevocable nonexclusive basis.
  • I understand that the presenting author must be a registered participant.
  • The Organizers reserve the right to remove from publication and/or presentation an abstract which does not comply with the above.